TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9378168

Group type: EXPERIMENTAL
Intervention: Carboplatin (C) 400 mg/m2 every three weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Carboplatin 350 mg/m2, ifosfamide (I) 5 g/m2 with mesna, vincristine (V) 1.4 mg/m2, and bleomycin (B) 30 mg every ten days (CIVB arm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carboplatin (C)
Number of subjects: 40
Study: 7903505

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg/kg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study: 3475430

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide + triamterene) with methyldopa if blood pressure remained elevated
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 840
Study: 31538149

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% prior to 0.5 mg/kg midazolam (group B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam (group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline 0.9% (placebo) with 0.5 mg/kg midazolam (group C)
Number of subjects: 63
Study: 30458625

Group type: EXPERIMENTAL
Intervention: Mirror visual feedback (MVF) combined with traditional rehabilitation (30 minutes MVF + 45 minutes traditional rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional rehabilitation (75 minutes)
Number of subjects: 40
Study: 27696490

Group type: EXPERIMENTAL
Intervention: Propofol (high, 3 μg/mL; medium, 1.5 μg/mL; low, 0.5 μg/mL; or no drug) and Remifentanil (high, 6 or 8 ng/mL; medium, 4 ng/mL; low, 2 ng/mL; or no drug)
Number of subjects: 60
Study: 26203169

Group type: EXPERIMENTAL
Intervention: Deworming drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated children in intervention schools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children in nearby non-intervention schools
Number of subjects: 0
Study: 24195209

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment of fire needles at bones combined with cupping and Tuina
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 100
Study: 21470872

Group type: EXPERIMENTAL
Intervention: Removal of anterior periaortic fat pad (AFP) during CABG (n=107)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Maintenance of anterior periaortic fat pad (AFP) during CABG (n=108)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Removal of AFP
Number of subjects: 215

Group type: COMPARATOR
Intervention: Maintenance of AFP
Number of subjects: 215
Study: 19673337

Group type: EXPERIMENTAL
Intervention: Chemotherapy (FOLFOX regimen) combined with Shenqi Fuzheng Injection (SFI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Chemotherapy (FOLFOX regimen) alone
Number of subjects: 152
Study: 16750678

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Balloon angioplasty (BA)
Number of subjects: 150
Study: 14559725

Group type: EXPERIMENTAL
Intervention: HIV-lipodystrophic patients
Number of subjects: 34
Study: 11288201

Group type: EXPERIMENTAL
Intervention: Progresse (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neurotin (reference formulation)
Number of subjects: 24
Study: 10920901

Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM (treatment group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: CHOP (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM (treatment group) in high grade malignant NHL
Number of subjects: 74

Group type: COMPARATOR
Intervention: CHOP (control group) in high grade malignant NHL
Number of subjects: 74
Study: 8392274

Group type: EXPERIMENTAL
Intervention: Treatment with estrogen/progesterone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 54
Study: 3554491

Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg three times daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 29729655

Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention (details on dosage and duration not available)
Number of subjects: 735
Study: 26769552

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 500

Group type: COMPARATOR
Intervention: Exercise Stress Testing (EST)
Number of subjects: 500
Study: 25041811

Group type: EXPERIMENTAL
Intervention: ABT-384 single-dose (1, 8, 20, 50, 120 and 240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABT-384 multiple-dose (1, 2, 4, 8, 20, 30 and 100 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for ABT-384
Number of subjects: 0
Study: 22951426

Group type: EXPERIMENTAL
Intervention: Oral cefditoren pivoxil 400mg once daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 82
Study: 20079602

Group type: EXPERIMENTAL
Intervention: 7.0- or 7.5-mm ETT
Number of subjects: 22

Group type: COMPARATOR
Intervention: 8.0-mm ETT
Number of subjects: 22
Study: 18028385

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia with subarachnoid morphine, bupivacaine, and fentanyl (MBF group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intermittent bolus epidural analgesia (EA group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Morphine and bupivacaine (MB group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Morphine (M group)
Number of subjects: 160
Study: 17054311

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: No preoperative radiotherapy
Number of subjects: 139
Study: 12773836

Group type: EXPERIMENTAL
Intervention: Women Take PRIDE program (self-management intervention)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 452
Study: 10685817

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) 100 units diluted in 1 ml saline, injected at five trigger points (0.2 ml each) via a 30 gauge needle.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (1 ml) as placebo control, injected at five trigger points.
Number of subjects: 26
Study: 9086150

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8200182

Group type: EXPERIMENTAL
Intervention: octreotide
Number of subjects: 9

Group type: COMPARATOR
Intervention: acute volume expansion alone
Number of subjects: 9
Study: 3923791

Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no contrast agent)
Number of subjects: 76
Study: 29306877

Group type: EXPERIMENTAL
Intervention: DQIP intervention (education, informatics, financial incentives)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Not applicable (control group of non-recruited practices)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DQIP intervention (self-reported adoption)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DQIP intervention (effectiveness)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: DQIP intervention (final multivariate model)
Number of subjects: 65
Study: 27631616

Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 30 seconds
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 60 seconds
Number of subjects: 3018

Group type: EXPERIMENTAL
Intervention: (hot‐to‐) cold shower for 90 seconds
Number of subjects: 3018

Group type: COMPARATOR
Intervention: Control group (no cold shower)
Number of subjects: 3018
Study: 23856361

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (for patients with CD for 2 years or less)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab (patients achieving deep remission)
Number of subjects: 0
Study: 22281799

Group type: EXPERIMENTAL
Intervention: RIPCpre plus RIPCpost
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 19966591

Group type: EXPERIMENTAL
Intervention: Short-rest intervals (SR) with a work rest ratio of approximately 1:3
Number of subjects: 34

Group type: COMPARATOR
Intervention: Long-rest intervals (LR) with a work rest ratio of approximately 1:6
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Short-rest intervals (SR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Long-rest intervals (LR)
Number of subjects: 34
Study: 18355366

Group type: EXPERIMENTAL
Intervention: Low-dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Conventional-dose HT (2 mg 17 beta‐estradiol and 1 mg NETA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Raloxifene (60 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202
Study: 15680144

Group type: EXPERIMENTAL
Intervention: Speakers producing disambiguating cues to syntactic ambiguity in instructions (Experiment 1 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speakers' awareness of situational ambiguity (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions with syntactic ambiguity (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye-tracking data (Experiment 3)
Number of subjects: 0
Study: 12767572

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (TTS 50 twice‐weekly)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 35
Study: 10488988

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.12 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.24 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ephedrine (both dosages)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trigeminal stimuli
Number of subjects: 24
Study: 8945044

Group type: EXPERIMENTAL
Intervention: Model 1400T lead (impregnated with steroid)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Model 1401T lead (not impregnated with steroid)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pacesetter Microny SR + 2425T VVIR pacemaker
Number of subjects: 54
Study: 1365502

Group type: EXPERIMENTAL
Intervention: roentgenovascular dilatation of one or two coronary arteries
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: noninvasive tests
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control coronarography
Number of subjects: 40
Study: 6358146

Group type: EXPERIMENTAL
Intervention: Starchex
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Calorex
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31627736

Group type: EXPERIMENTAL
Intervention: Community-level WASH intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular deworming with albendazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Household characteristics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infection with hookworm (Necator americanus)
Number of subjects: 0
Study: 30048306

Group type: EXPERIMENTAL
Intervention: Prehabilitation (nutritional counseling and exercise)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 118
Study: 27384580

Group type: EXPERIMENTAL
Intervention: Amino acid supplement (SUPP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 24782447

Group type: EXPERIMENTAL
Intervention: Vestibular suppressant (dimenhydrinate 50 mg per day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 150
Study: 22048284

Group type: EXPERIMENTAL
Intervention: TIVA with remifentanil-propofol (group R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIVA with fentanyl-propofol (group F)
Number of subjects: 40
Study: 19114222

Group type: EXPERIMENTAL
Intervention: Yoga (n=18)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Supportive therapy (control, n=20)
Number of subjects: 98
Study: 17172316

Group type: EXPERIMENTAL
Intervention: High-intensity combined endurance and resistance exercise training program (16 weeks, 3 endurance sessions and 2 resistance sessions per week)
Number of subjects: 9
Study: 14668570

Group type: EXPERIMENTAL
Intervention: Morning dosing with cilnidipine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bedtime dosing with cilnidipine
Number of subjects: 13
Study: 12482110

Group type: EXPERIMENTAL
Intervention: Pulsed estrogen therapy (Aerodiol®)
Number of subjects: 659
Study: 9797183

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14
Study: 7639204

Group type: EXPERIMENTAL
Intervention: Computerized Diagnostic Interview Schedule (C-DIS)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM-III-R (SCID)
Number of subjects: 173

Group type: COMPARATOR
Intervention: C-DIS
Number of subjects: 173

Group type: COMPARATOR
Intervention: SCID
Number of subjects: 173
Study: 2577283

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Digoxin and Xamoterol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Digoxin or Xamoterol
Number of subjects: 19
Study: 339940

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus immunotherapy with BCG and irradiated allogeneic blast cells
Number of subjects: 71

Group type: COMPARATOR
Intervention: Maintenance chemotherapy alone
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Immunotherapy with BCG and irradiated allogeneic blast cells
Number of subjects: 71
Study: 31735108

Group type: EXPERIMENTAL
Intervention: Venography plus angioplasty (n=86)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Favorable venograms (n=38)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Venography (sham; n=44)
Number of subjects: 130
Study: 31534559

Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training for 10-12 weeks targeting concept formation, object categorization, and decision-making abilities.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Categorization Program (CP) training for older adults (experimental group).
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no CP training).
Number of subjects: 58
Study: 27467517

Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Russian belt (RB)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 47
Study: 26537599

Group type: EXPERIMENTAL
Intervention: Family Therapy (FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 23386704

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (4000 IU/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both groups (High-dose vitamin D and Placebo)
Number of subjects: 116
Study: 21499826

Group type: EXPERIMENTAL
Intervention: Neighborhood SES (socio-economic status)
Number of subjects: 15889

Group type: EXPERIMENTAL
Intervention: Neighborhood walkability
Number of subjects: 15889

Group type: COMPARATOR
Intervention: Neighborhood SES (highest decile)
Number of subjects: 15889
Study: 19802686

Group type: EXPERIMENTAL
Intervention: One-leg standing (OLS) test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions to improve OLS time
Number of subjects: 0
Study: 17618934

Group type: EXPERIMENTAL
Intervention: Immediate loading (n=33)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Early loading (n=21)
Number of subjects: 51
Study: 15172090

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11676155

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMLR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative medical treatment
Number of subjects: 0
Study: 9578967

Group type: EXPERIMENTAL
Intervention: Elevating peak inspiratory pressure (PIP) in Group 1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prolonging inspiratory time (T1) in Group 1
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Raising positive end expiratory pressure (PEEP) in Group 2
Number of subjects: 22
Study: 8066558

Group type: EXPERIMENTAL
Intervention: Auranofin (3 mg orally twice a day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 19
Study: 3378222

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent bolus of cis-diamminedichloroplatinum(II) at 30 mg/m2/day for 5 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cis-diamminedichloroplatinum(II)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent bolus of cis-diamminedichloroplatinum(II)
Number of subjects: 11
Study: 28951057

Group type: EXPERIMENTAL
Intervention: Grab-and-go style breakfast carts and policies
Number of subjects: 364
Study: 27824882

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits and were encouraged to distribute one to their male partner or use both for testing as a couple.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Comparison group; participants received an invitation card for clinic-based HIV testing and were encouraged to distribute the card to their male partner.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) group; participants received two oral-fluid-based HIV test kits.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Comparison group; participants received an invitation card for clinic-based HIV testing.
Number of subjects: 600
Study: 24731493

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tamoxifen (Control)
Number of subjects: 12
Study: 23853004

Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 183

Group type: COMPARATOR
Intervention: Suspension
Number of subjects: 183

Group type: COMPARATOR
Intervention: Powder
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Overall formulations
Number of subjects: 183
Study: 20220530

Group type: EXPERIMENTAL
Intervention: Resource facilitation (RF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 22
Study: 18801398

Group type: EXPERIMENTAL
Intervention: 30 microg H5 HA with AlPO4 adjuvant
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 45 microg H5 HA with AlPO4 adjuvant
Number of subjects: 150
Study: 16529658

Group type: EXPERIMENTAL
Intervention: All-arthroscopic repair
Number of subjects: 250

Group type: COMPARATOR
Intervention: Mini-open repair
Number of subjects: 250
Study: 12810608

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 21
Study: 11732148

Group type: EXPERIMENTAL
Intervention: artesunate (4 mg/kg on day 0 and 2 mg/kg on days 1‐4)
Number of subjects: 62

Group type: COMPARATOR
Intervention: mefloquine (10 mg/kg followed by 5 mg/kg at 6 h)
Number of subjects: 62

Group type: COMPARATOR
Intervention: mefloquine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: artesunate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: artesunate plus mefloquine
Number of subjects: 62
Study: 9203892

Group type: EXPERIMENTAL
Intervention: Glossopharyngeal nerve block with bupivacaine 0.5% and adrenaline 1:200,000
Number of subjects: 108

Group type: COMPARATOR
Intervention: Morphine alone (no glossopharyngeal nerve block)
Number of subjects: 108
Study: 7963156

Group type: EXPERIMENTAL
Intervention: Prednisone (single oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2824031

Group type: EXPERIMENTAL
Intervention: gamma-interferon
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 29879948

Group type: EXPERIMENTAL
Intervention: I‐STAND intervention (12-week program with 6 health coaching contacts, a study workbook, a Jawbone UP band, and feedback from an activPAL device)
Number of subjects: 22
Study: 28095077

Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 16
Study: 26575060

Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg/d for 5 days)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study: 23237386

Group type: EXPERIMENTAL
Intervention: Project Tomato intervention
Number of subjects: 658

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 658
Study: 21146469

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both opioids
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 139
Study: 18344552

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.175% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 2)
Number of subjects: 164

Group type: COMPARATOR
Intervention: levobupivacaine 0.15% with 0.5 mg kg(‐1) S(+)‐ketamine (Group 1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: levobupivacaine 0.2% (Group 3)
Number of subjects: 164
Study: 17152422

Group type: EXPERIMENTAL
Intervention: Suturing
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Steristrips
Number of subjects: 160

Group type: COMPARATOR
Intervention: Simple dressing
Number of subjects: 160
Study: 14769156

Group type: EXPERIMENTAL
Intervention: Game (Jugando en salud: dengue) practiced three times a week for 60 days with theoretical materials about dengue
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Theoretical materials only (group no. 2)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Regular learning program (control group)
Number of subjects: 621